New UC-II® joint-health research findings were presented by InterHealth’s director of research and development, Zainulabedin M. Saiyed, PhD, FACN at the Scripps 12th annual natural supplement conference in San Diego, Jan. 15 to 18.
The presentation summarized the pooled results from two identically designed, randomized, double-blind, placebo-controlled studies in people with osteoarthritis. A total of 186 subjects took 40 mg a day of UC-II®; 1,500 mg glucosamine hydrochloride plus 1,200 mg chondroitin sulfate (GC) or a placebo for 180 days. The primary endpoint was defined as the change in overall WOMAC score by day 180 versus placebo. Secondary endpoints encompassed reductions in Lequesne Functional Index (LFI), Visual Analog Scale (VAS) for pain and the WOMAC subscales for pain, stiffness and physical function.
At study conclusion, statistically significant reductions in overall WOMAC score was observed in the UC-II group compared to placebo. Driving the change in overall WOMAC score for the UC-II group were statistically significant reductions in the WOMAC pain, stiffness and physical function subscales. The UC-II group also demonstrated a significant reduction in total LFI and mean VAS scores compared to placebo. The GC group did not achieve statistical significance versus placebo for any of these clinical endpoints.
UC-II is a novel patented collagen with undenatured type II collagen derived from chicken sternum cartilage. Previous preclinical and clinical studies support the safety and efficacy of UC-II in promoting joint comfort, mobility and flexibility in healthy as well as osteoarthritic populations. Through ongoing clinical research, InterHealth strives to provide superior ingredients to manufacturers and consumers.
UC-II’s presentation at the Scripps meeting marks the first public presentation of the research results. A copy of the poster presentation is available upon request through InterHealth.